Clinical relevance of minimal residual disease monitoring in non-Hodgkin's lymphomas

A critical reappraisal of molecular strategies

P. Corradini, M. Ladetto, A. Pileri, C. Tarella

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Although current treatments can induce clinical complete remissions in the vast majority of patients with indolent lymphoma, most of them actually relapse, because of the persistence of residual tumor cells which are undetectable using conventional diagnostic procedures. Polymerase chain reaction (PCR)-based methods are increasingly used for minimal residual disease detection (MRD), and provide useful prognostic information. In this review, current approaches for MRD detection in indolent lymphomas are summarized. In addition, the prognostic aspects of molecular monitoring after transplantation procedures are discussed. The experience accumulated over the past decade shows that PCR analysis has a prognostic impact in several therapeutic programs including conventional and high-dose regimens. Major advantages coming from the introduction of molecular monitoring in clinical programs have been: (1) a rapid evaluation of the anti-tumor activity of innovative treatments; and (2) an early identification of patients with a high-risk of disease recurrence.

Original languageEnglish
Pages (from-to)1691-1695
Number of pages5
JournalLeukemia
Volume13
Issue number11
Publication statusPublished - 1999

Fingerprint

Residual Neoplasm
Non-Hodgkin's Lymphoma
Lymphoma
Recurrence
Polymerase Chain Reaction
Therapeutics
Transplantation
Neoplasms

Keywords

  • Minimal residual disease in lymphomas

ASJC Scopus subject areas

  • Hematology
  • Cancer Research

Cite this

Clinical relevance of minimal residual disease monitoring in non-Hodgkin's lymphomas : A critical reappraisal of molecular strategies. / Corradini, P.; Ladetto, M.; Pileri, A.; Tarella, C.

In: Leukemia, Vol. 13, No. 11, 1999, p. 1691-1695.

Research output: Contribution to journalArticle

@article{b6e299d0f9e242299dd14e6a6f273a2b,
title = "Clinical relevance of minimal residual disease monitoring in non-Hodgkin's lymphomas: A critical reappraisal of molecular strategies",
abstract = "Although current treatments can induce clinical complete remissions in the vast majority of patients with indolent lymphoma, most of them actually relapse, because of the persistence of residual tumor cells which are undetectable using conventional diagnostic procedures. Polymerase chain reaction (PCR)-based methods are increasingly used for minimal residual disease detection (MRD), and provide useful prognostic information. In this review, current approaches for MRD detection in indolent lymphomas are summarized. In addition, the prognostic aspects of molecular monitoring after transplantation procedures are discussed. The experience accumulated over the past decade shows that PCR analysis has a prognostic impact in several therapeutic programs including conventional and high-dose regimens. Major advantages coming from the introduction of molecular monitoring in clinical programs have been: (1) a rapid evaluation of the anti-tumor activity of innovative treatments; and (2) an early identification of patients with a high-risk of disease recurrence.",
keywords = "Minimal residual disease in lymphomas",
author = "P. Corradini and M. Ladetto and A. Pileri and C. Tarella",
year = "1999",
language = "English",
volume = "13",
pages = "1691--1695",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "11",

}

TY - JOUR

T1 - Clinical relevance of minimal residual disease monitoring in non-Hodgkin's lymphomas

T2 - A critical reappraisal of molecular strategies

AU - Corradini, P.

AU - Ladetto, M.

AU - Pileri, A.

AU - Tarella, C.

PY - 1999

Y1 - 1999

N2 - Although current treatments can induce clinical complete remissions in the vast majority of patients with indolent lymphoma, most of them actually relapse, because of the persistence of residual tumor cells which are undetectable using conventional diagnostic procedures. Polymerase chain reaction (PCR)-based methods are increasingly used for minimal residual disease detection (MRD), and provide useful prognostic information. In this review, current approaches for MRD detection in indolent lymphomas are summarized. In addition, the prognostic aspects of molecular monitoring after transplantation procedures are discussed. The experience accumulated over the past decade shows that PCR analysis has a prognostic impact in several therapeutic programs including conventional and high-dose regimens. Major advantages coming from the introduction of molecular monitoring in clinical programs have been: (1) a rapid evaluation of the anti-tumor activity of innovative treatments; and (2) an early identification of patients with a high-risk of disease recurrence.

AB - Although current treatments can induce clinical complete remissions in the vast majority of patients with indolent lymphoma, most of them actually relapse, because of the persistence of residual tumor cells which are undetectable using conventional diagnostic procedures. Polymerase chain reaction (PCR)-based methods are increasingly used for minimal residual disease detection (MRD), and provide useful prognostic information. In this review, current approaches for MRD detection in indolent lymphomas are summarized. In addition, the prognostic aspects of molecular monitoring after transplantation procedures are discussed. The experience accumulated over the past decade shows that PCR analysis has a prognostic impact in several therapeutic programs including conventional and high-dose regimens. Major advantages coming from the introduction of molecular monitoring in clinical programs have been: (1) a rapid evaluation of the anti-tumor activity of innovative treatments; and (2) an early identification of patients with a high-risk of disease recurrence.

KW - Minimal residual disease in lymphomas

UR - http://www.scopus.com/inward/record.url?scp=0032718332&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032718332&partnerID=8YFLogxK

M3 - Article

VL - 13

SP - 1691

EP - 1695

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 11

ER -